Abstract

SUMMARYAnimal models mimicking human diseases have been used extensively to study the pathogenesis of autoimmune diseases and the efficacy of potential therapeutics. They are, however, limited with regard to their similarity to the human disease and cannot be used if the antagonist and its cognate receptor require high similarity in structure or binding. Here, we examine the induction of oxazolone-mediated features of atopic dermatitis (AD) in NOD-scid IL2Rγnull mice engrafted with human peripheral blood mononuclear cells (PBMC). The mice developed the same symptoms as immunocompetent BALB/c mice. Histological alterations induced by oxazolone were characterized by keratosis, epithelial hyperplasia and influx of inflammatory cells into the dermis and epidermis. The cellular infiltrate was identified as human leukocytes, with T cells being the major constituent. In addition, oxazolone increased human serum IgE levels. The response, however, required the engraftment of PBMC derived from patients suffering from AD, which suggests that this model reflects the immunological status of the donor. Taken together, the model described here has the potential to evaluate the efficacy of therapeutics targeting human lymphocytes in vivo and, in addition, might be developed further to elucidate molecular mechanisms inducing and sustaining flares of the disease.

Highlights

  • A large number of new drug candidates fail in clinical trials for a variety of reasons, including insufficient activity or unforeseen toxicity

  • This study describes a new model of Atopic dermatitis (AD) involving oxazolone-induced pathology in immune-compromised mice engrafted with human peripheral mononuclear cells (PBMCs)

  • Mice engrafted with peripheral blood mononuclear cells (PBMC) from AD patients – but not with PBMCs from healthy donors – developed the same pathological signs as observed in immunocompetent oxazolone-exposed mice, including epithelial hyperplasia, IgE secretion and infiltration of inflammatory cells into the dermis and epidermis

Read more

Summary

Introduction

A large number of new drug candidates fail in clinical trials for a variety of reasons, including insufficient activity or unforeseen toxicity. This most probably reflects the predictive quality of the preclinical animal models and the difficulty in translating positive data in animal models to the patient. The pathophysiological mechanisms in the genetically heterogeneous and often aged patient population differ markedly from those observed in animals. This is relevant for the 12-week-old inbred specific pathogen-free (SPF)-bred mouse, which is used widely for the development of disease models and efficacy profiling of new drugs to include potential treatment of chronic immuno-inflammatory disorders. AD is a T-helper cell type 2 (TH2)-driven inflammation, with interleukin-4 (IL-4) and interleukin-13 (IL-13) playing key roles in Received 18 November 2011; Accepted 15 July 2012

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call